Enveric Biosciences, Inc.
ENVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -267.13 | 0.05 | -0.08 |
| FCF Yield | -285.56% | -28.61% | -22.48% | -3.74% |
| EV / EBITDA | -0.05 | -2.79 | -3.14 | -4.88 |
| Quality | ||||
| ROIC | -605.30% | -842.19% | -117.79% | -225.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.82 | 0.93 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 45.20% | 20.48% | -43.89% | -213.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.14 | 0.90 | 0.27 |
| Interest Coverage | 0.00 | -4,435.93 | -3,802.90 | -6,264.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -564.28 | -1,090.25 | -388.55 | -365.95 |